Drugs

Early treatment with the anti-CD3 monoclonal antibody teplizumab may help to preserve β-cell function in children and adolescents with newly diagnosed type 1 diabetes, results of the phase 3 PROTECT study show.

Automated insulin delivery reduces hypoglycemia in people with type 1 diabetes at increased risk, improving their time spent in target glucose range.

Result from ONWARDS 5 trial show weekly insulin icodec plus a dosing app offers greater reductions in glycated hemoglobin than daily basal insulin analogs for type 2 diabetes.

A retrospective analysis has found a significantly higher incidence of hyperglycemia among breast cancer patients treated with alpelisib in standard care than on clinical trials.

Teplizumab consistently preserves the function of β-cells in people with type 1 diabetes as measured by higher C-peptide levels at 1 and 2 years post-treatment.

Novel model for risk prediction of kidney disease progression and efficacy of SGLT2 inhibition in patients with type 2 diabetes.

SGLT2 inhibitors and GLP-1 receptor agonists appear to offer the best protection against major adverse cardiovascular events in people with type 2 diabetes.

Treating people with type 2 diabetes with the triple agonist retatrutide shows promising improvements in both glycemic control and reduction in obesity.